A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001
- Conditions
- Steroid-refractory ulcerative colitisMedDRA version: 8.1Level: LLTClassification code 10009900Term: Colitis ulcerative
- Registration Number
- EUCTR2006-004303-19-GB
- Lead Sponsor
- Cerimon Pharmaceuticals, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 135
Subjects must satisfy all of the following inclusion criteria to be eligible for the study:
1.Male or female subjects, age =18 years and =75 years
2.Weight of 40 kg or greater
3.Signed a current IRB/IEC-approved informed consent form
4.Diagnosis of ulcerative colitis confirmed through screening endoscopy. A
rectal biopsy will be obtained and reviewed by a local pathologist.
Histopathology must be compatible with the diagnosis.
5.Extent of disease must involve at least the left colon (i.e., greater than 15
cm beyond the anal verge as the endoscope is withdrawn)
6.Moderate to severe disease, defined as a total Mayo score of 6 points or
greater, including an endoscopic subscore of 2 points or greater. Systemic
features of tachycardia, fever, and/or significant anemia should not be
present
7.Steroid-refractory disease, defined as moderate to severe disease,
without systemic features , despite treatment with prednisone 40 – 50
mg/day (or other oral steroid at equivalent dose) orally for a minimum of
14 days immediately preceding study entry
8.Concomitant azathioprine or 6-mercaptopurine treatment is permitted
during the study if initiated at least 12 weeks before study entry, and if
the dose has not been changed or stopped for at least 8 weeks before
study entry.
9.Concomitant oral aminosalicylate treatment is permitted during the study if
initiated at least 4 weeks before study entry, and if the dose has not been
changed or stopped during this time.
10.Females of childbearing potential must use an effective birth control
method, and be willing to continue birth control during the study, and for 4
months after the last dose of study drug.
11.Females of non-childbearing potential should be surgically sterile (bilateral
tubal ligation with surgery at least 6 months before study entry,
hysterectomy, or bilateral oophorectomy at least 2 months before study
entry) or post-menopausal for at least 2 years.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Presence of any of the following conditions will exclude the subject from eligibility for the study:
1.Prior treatment with basiliximab or daclizumab at any time
2.Prior treatment with cyclosporine, tacrolimus, methotrexate, or any anti-
TNF agent within 3 months before study entry
3.Prior treatment with parenteral corticosteroids within 14 days before
study entry
4.Initiation of azathioprine or 6-mercaptopurine treatment less than 12
weeks before study entry, or discontinuation or change of dose less than
8 weeks before study entry
5.Initiation of oral aminosalicylate treatment , or change of dose, or
discontinuation less than 4 weeks before study entry
6.Rectally administered medications containing corticosteroids or
aminosalicylates within 2 weeks before screening endoscopy
7.If currently taking a nonsteroidal anti-inflammatory agent (NSAID), the
inability to discontinue NSAID use during study participation
8.Intolerance or inability to continue oral corticosteroids during the trial
9. Stool studies that show presence of ova and parasites, significant
bacterial pathogens, or C. difficile toxin
10.Colitis that is indeterminate, suggestive of Crohn’s disease, or isolated to
the rectum, based on endoscopic and/or biopsy findings
11.Presence of toxic megacolon
12.Severely ill patients as evidenced by greater than 6 episodes of loose
stools, all of them bloody, during a 24-hour period within the screening
window, concurrent with any of the following systemic features:
-Heart rate >90 beats/min at rest
-Temperature >37.8 degrees C
-Hemoglobin <10.5 g/dL
13.Laboratory values as follows:
-Hemoglobin <8.5 g/dL
-WBC <3.0 x 10E9/L
-Neutrophils <1.5 x 10E9 /L
-Lymphocytes <0.5 x 10E9 /L
-Platelets <100 x 10E9 /L
-AST (SGOT) >3 times upper limit of normal
-ALT (SGPT) >3 times upper limit of normal
14.Pregnant or breast-feeding female patients
15.Chest radiograph abnormalities consistent with an infectious process
16.Known HIV, or viral Hepatitis B or C infection
17.History of or exposure to tuberculosis within 6 months before study entry
18. History of central nervous system demyelinating disorder
19.History of colonic dysplasia
20.History of malignancy during the previous 5 years or current malignancy,
with exception of adequately treated non-melanoma skin cancer or in situ
carcinoma of the cervix
21.History of varicella, herpes zoster, or severe viral infection within 6 weeks
before study entry, exposure to varicella within 21 days before study
entry, or vaccination with live virus within 4 weeks before study entry
22.Any ECG abnormalities unless approved by the Medical Monitor
23.Treatment with an investigational drug or device within 30 days before
study entry
24.Treatment with an investigational biologic within 6 months before study
entry
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method